Starling Oncology Wt Receivables

The latest receivables for STLNW is $67M as of June 2026. That compares with $56M in the prior-year period — up 19.3% year over year. Investors often review this figure alongside Starling Oncology Wt's historical trend and sector peers before judging valuation or financial health.

Over the past year, STLNW's receivables moved from $56M to $67M — a 19.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Starling Oncology Wt's operating scale or balance-sheet position.

A receivables figure of $67M for STLNW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting STLNW's receivables ($67M), review year-over-year change from $56M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.